康芝药业 reported revenue of ¥0.14B for the period ended 2026-06-30, -37.7% year on year. Net income was ¥-0.03B, a -23.1% net margin on a 54.7% gross margin. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.14B | -37.7% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥-0.03B | — |
| Net income | ¥-0.03B | — |
| Gross margin | 54.7% | Net margin -23.1% |
| Revenue Q/Q | -50.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.07B | 45.3% |
| R&D | ¥0.01B | 4.4% |
| SG&A | ¥0.10B | 68.1% |
| Tax & other | ¥0.01B | 4.1% |
| Item | Amount |
|---|---|
| Total assets | ¥1.71B |
| Total liabilities | ¥0.82B |
| Shareholders' equity | ¥0.89B |
| Equity / assets | 51.9% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 34% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST荃银 ・ 长信科技 ・ *ST金灵 ・ 科新机电 ・ 金刚光伏 ・ 国联水产 ・ 华伍股份 ・ ST易联众 ・ 智云股份 ・ 高新兴 ・ 尤洛卡 ・ 双林股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies